Insider transactions
David Raben, Bicara Therapeutics Inc's chief medical officer, sold 5,500 shares of the company's common stock on March 25, 2026, for an aggregate value of approximately $104,229. The reported sale prices ranged from $18.55 to $19.36 per share.
Options exercise and holdings
On the same date, Raben exercised options that allowed him to acquire 5,500 additional shares of Bicara common stock at a strike price of $3.7898 per share, producing a stated total value of $20,843 for the exercise. After completing both the sale and the option exercise, Raben is reported to directly own 55,286 shares of Bicara Therapeutics Inc.
Market context and timing
At the time of the transactions, Bicara's shares were trading at $18.92, a level close to the company's 52-week high of $20.25, and reflecting a 62% rally over the prior six months. The timing of the insider activity comes four days before Bicara's scheduled earnings release on March 30.
Valuation signal from InvestingPro
Separately, analysis from InvestingPro is cited indicating that the stock appears overvalued relative to its Fair Value estimate. That assessment is noted alongside the disclosure of the insider activity.
Corporate financing
Bicara recently completed a substantial equity offering that raised approximately $172.5 million through the sale of common stock and pre-funded warrants. The underwriters' option tied to that offering was fully exercised and contributed to the total gross proceeds before expenses. Earlier disclosures around the offering indicated an initial pricing at $16 per share with an aim to raise roughly $150 million before underwriting discounts and commissions.
Analyst coverage
On the analyst front, BofA Securities began coverage of Bicara with a Buy rating and a $35 price target, citing potential for the company’s lead candidate, ficerafusp alfa, in the treatment of head and neck cancer. Citizens reiterated its Market Outperform rating and maintained a $31 price target. These notes form part of a backdrop of active financial activity and external interest in the company.
What this record shows
The compiled facts outline concurrent insider selling and option exercise, a significant capital raise, and renewed analyst engagement, all occurring as the company approaches an earnings announcement. The record presented here is limited to reported transactions, offering details, analyst ratings, and the InvestingPro valuation note.